Kovo HealthTech Corporation to Begin Trading on TSX Venture Exchange
Vancouver, British Columbia (Newsfile Corp. - June 3, 2021) - Kovo HealthTech Corporation (TSXV: KOVO) ( Kovo or the Company ), a leader in Revenue Cycle Management ( RCM ) and healthcare technology, is pleased to announce that its common shares will commence trading on the TSX Venture Exchange (the TSXV ) at the open of the market on June 4, 2021 under the symbol KOVO .
Kovo is a growing healthcare technology and services company that specializes in RCM services and software for US healthcare clinics, hospitals and private practices. RCM is a process used by healthcare providers in the US and globally to digitally track and manage patient care registration, services, billing and payments in a seamless way. Effective RCM practices are essential to ensure health care settings maintain the financial viability that allows them to provide ongoing quality care for their patients.
Hunt has begun for 2021 Canadian CIO of the Year | IT World Canada News itworldcanada.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itworldcanada.com Daily Mail and Mail on Sunday newspapers.
12.20.20 Cleaning Process Development: Time To Clean Studies & The Cleaning Assurance Level For Pharmaceutical Products
By Ruijin Song and Andrew Walsh, Center for Pharmaceutical Cleaning Innovation (CPCI)
A simple time-to-clean study can provide a rapid and efficient way to evaluate the behavior of a product during cleaning and obtain a reasonable estimate of the actual amount of time needed to achieve acceptable cleaning.
By Mavra Nasir, Ph.D., Crystal Hsu, and Peter Bak, Ph.D., Back Bay Life Science Advisors
In Part 1 of this three-part series, we discussed nonalcoholic steatohepatitis (NASH), the market for treatments, the first wave of NASH drugs (at Phase 3) poised to change the management paradigm, and the currently ambiguous pricing/reimbursement landscape. Here in Part 2, we look at the most promising second wave of NASH drugs.
Analysis Of The Non-alcoholic Steatohepatitis (NASH) Drug Pipeline & Market: The M&A And Commercial Landscape
By Mavra Nasir, Ph.D., Crystal Hsu, and Peter Bak, Ph.D., Back Bay Life Science Advisors
In Part 1 and Part 2 of this three-part series, we covered the varied complexities of NASH driving an extremely challenging development landscape, along with the growing prevalence of NASH that has the life sciences industry in a race to develop a successful asset.
In this last part of the series, we cover the M&A and commercial landscape implications, including historical and future deal trends, challenges in developing a successful commercial strategy, and what to watch out for as the NASH industry continues to reach new milestones.